As more AI-driven healthcare products are brought to market, how can regulators keep pace with this rapidly evolving technology?
Artificial intelligence (AI) is becoming a force to be reckoned with in healthcare. Over the last decade or so, AI-based healthcare products have moved out of the proof-of-concept stage and have begun to rewrite our understanding of what might be possible.
To cite just a few examples: deep learning techniques have been used in dermatology to diagnose skin cancer, and in radiology to make better sense of CT scans. Surgeons are using robots integrated with AI, while pharma companies are using convolutional neural networks to identify promising drug candidates.
AI-based wearable devices are routinely used to monitor patients, flagging up any changes to their vital signs. There are even AI-based triage tools for Covid-19, which can determine who needs a PCR test.